Feeds:
Posts
Comments

Archive for December, 2019

The Future of Synthetic Biology

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, Biological Engineering, tagged , , , on December 25, 2019| Leave a Comment »

The Future of Synthetic Biology

Reporter: Irina Robu, PhD

With an estimated global evaluation of around $14 billion US, synthetic biology is a rapidly accelerating market. Nonetheless while the growth of the market has been remarkable, the ttrue impact has not yet been seen. The era of AI will quickly increase the pace of discovery, and produce materials not seen in nature, through extrapolation and generative design. The extraordinary is now possible: producing spider silk without spiders, egg proteins without chickens and fragrances without flowers.

Synthetic biology companies are associating with fashion designers as well as forming ‘organism foundries. Rapidly, AI will utilize its learning of the natural world to make guided inferences which produce entirely new materials. From a technology perspective, we’re experiencing an explosion of capability that will be invasive in the next 3-5 years. Language models have come a long way, to the point where full models are being kept private so as not to endanger the public.

Already today, the average person has the ability to start their own commercial space venture for less than the cost of a juice franchise. PwC Australia’s Charmaine Green believes secret trends can hide among obvious ones. She outlines three trends leading to her hypothesis that Australia is well placed to become the global creative hub for video game development.

Economies like Australia are situated to capitalize on this trend, and video game development can become a permanent and substantial part of the economy. In Australia, Green argues, we have all the basic elements needed: high ingenuity, creative risk taking, and the freedom and flexibility that comes with the country’s small-to-mid studios.

SOURCE

https://www.digitalpulse.pwc.com.au/top-tech-trends-debate-2019/

Read Full Post »

Self-propelled Liposomes as a Drug Delivery System

Posted in 3D Printing for Medical Application, Drug Delivery Platform Technology, tagged , , , on December 25, 2019| Leave a Comment »

Self-propelled Liposomes as a Drug Delivery System

Reporter: Irina Robu, PhD

Liposomes are small artificial vesicles of spherical shape that can be created from cholesterol and natural non-toxic phospholipids. As a result of their size and hydrophobic and hydrophilic character, liposomes are promising systems for drug delivery. Liposome properties diverge considerably with lipid composition, surface charge, size, and the method of preparation. Scientists at Penn State developed self-propelled liposomes that migrate away and/or towards chemical signals, making it possible for self-directed drug delivery vehicles that can actively target a specific area of the body. Besides, the choice of bilayer components controls the ‘rigidity’ or ‘fluidity’ and the charge of the bilayer. Countless liposomes proposed for drug delivery are tissue-specific, since of antibodies on their surface bind to the target tissue when they encounter it. The technology may help to enhance efficacy and reduce side-effects of drugs in a variation of applications.

Yet, the key to drug delivery is enhancing the specificity and affinity of a drug delivery vehicle for its target tissue. As the drawbacks of conventional drug therapies, scientists are developing an extensive variability of drug delivery vehicles including nanoparticles, biomaterials, and implantable devices, to increase drug accumulation at a target site in the body and reduce side-effects elsewhere. To address the drawbacks, these researchers developed a type of liposome that can actively propel itself near a chemical signal in the body, such as a chemical attractant released by a target tissue.

The liposomes proposed by Penn researchers are covered in enzymes that react with specific substrates to produce energy, which can help to push the liposomes along, through a phenomenon called chemotaxis. By changing the enzymes coating the liposomes, the investigators can tune this chemotaxis and permit the particles to either move towards or away the chemical signal. This could aid the particles to gravitate near certain tissues, and possibly avoid others in the body.
Currently, the are still developing the liposomes, and hope that they will be able to use them for drug delivery soon
SOURCE
https://www.sciencedaily.com/releases/2019/11/191118110928.htm

Read Full Post »

3D Printing Used as New Tool for Radiologists

Posted in 3D Printing for Medical Application, Bioengineering & reverse engineering design, Materials Science & Engineering, tagged , , , , , on December 23, 2019| Leave a Comment »

3D Printing Used as New Tool for Radiologists

Reporter: Irina Robu, PhD

3D printing is a technique that has gained immense popularity for its ability to create 3D structures in art, jewelry, engineering, medicine. In this case, radiologists use 3D printing to transform a 2D scan into 3D visualization of a patient’s anatomy. Radiologists use their unique skills to visualize the anatomy of the organs of interest which give them a large advantage in communicating with patients as well as surgical teams.

The 3D printed anatomical models have proved valuable in providing a better understanding of complex anatomies and being used as a tangible aid for pre-surgical planning. It gives the patient a clear understanding of what is happening and it provides a great value when it comes to patient specific care. However, 3D modelling is essential at the beginning but it can also be a useful tool for surgeons. The list of medical 3D printing benefits is infinite. Just recently, a scientific team at University of Minnesota constructed their own patient specific 3D organ model based on MRI scans and prostate tissue samples of patients. The organs allow surgeons to plan and rehearse surgery.
In addition to researchers at University of Minnesota, Siemens Health engineers also created a platform to make medical apps that can be accessible throughout hospitals. In addition, Siemens Health partnered up with Materialise to make 3D printing software an integral part of the radiology workflow.

Hence, using 3D bioprinting is a desirable path to follow for radiologist. Not only they get to interpret anatomy, but now they can use 3D bioprinting as a state of the art tool that empower them to provide immense value to an audience that stretches from patient to practitioner.

SOURCE

https://www.bioportfolio.com/news/article/4177601/3D-Printing-Used-as-New-Tool-for-Radiologists.html

Read Full Post »

The Problem and Challenges of Commercialization

Posted in Commercialization, Drug Development Process, Pharmacovigilance, Rapid automation of plasma protein pools on December 23, 2019| Leave a Comment »

The Problem and Challenges of Commercialization

Curator and Reporter: Joel Shertok, PhD

 

As the old saying goes,

Anybody can do something once; the problem is: can you do it twice, or for that matter, over and over again?

This is the essential issue faced by those personnel in the throes of the commercialization process.

Any successful commercial process has to meet a number of criteria:

  1. The process must be reproducible — it must yield the same product/results given the same inputs.
  2. The process must be economically viable: given the constraints of raw material, energy, and labor costs, depreciation schedules for equipment, expected process failures, R/D, Marketing, and Sales support costs, the process needs to yield both a profit and positive cash flow
  3. The process should be implemented using readily available commercial components and control instrumentation. On occasion, successful implementation of a project will require specialized components; however these components themselves must meet the criteria for successful commercialization
  4. The process must be “simple” enough so that suitably trained operators can manage the process. A unit that requires Ph.D.’s to maintain operations is doomed to failure

History is replete with novel processes that worked on the lab scale, but were failures when a commercial operation was attempted. The issues that are most responsible for lab-to-production failure are listed under the general classification of “scale-up”. Scale-up principles are covered in my monograph, “The Art of Scale-up” (www.artofscaleup.com), but in general follow these rules:

  • Identification of those process parameters that will have major impact on commercial viability: reaction kinetics, mass transfer vs. temperature/kinetic control; if multi-phase systems are involved, the type and energy of required stirring; heat transfer considerations; side reactions; etc.

  • Materials of construction; raw material and product hazards; etc.

  • Regulatory considerations: FDA, OSHA, EPA.

Failure to address any of these issues prior to commercialization will lead to surprises during commercialization.

In addition to the engineering/scale-up aspects of commercialization, there are several other criteria that may need attention:

  1. When to launch a product – where will the new product fit into the overall corporate product portfolio?
  2. Where is the proper location to launch?  A product aimed at flu symptom suppression in cold-weather conditions may not do well in Florida; ….. super-sweet tea does well in the South, and not so well in New England, so that a product to replace sugar might do well in the South.
  3. Who is going to use the product?  Are you targeting doctor’s offices, hospitals, or direct to consumer routes?
  4. How to launch – social media and “influencers” have given rise to new avenues of product introductions.

The old aphorism of “measure twice, cut once” has a special resonance when doing commercialization of a new process or product. The more the process is thought out ahead of time, the less issues there will be down the road. In the commercial world, there is constant pressure to rush things to meet management deadlines, which always leads to problems and extra expense. A crusty of R/D chemist once remarked, “There is never time to do it right, but always time to do it twice.” Everyone needs to keep this in the back of their mind

Read Full Post »

Diversity and Health Disparity Issues Need to be Addressed for GWAS and Precision Medicine Studies

Posted in and Bioethics, Bio-Ethics, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Cancer Genomics, Childhood cancer, Genome Biology, Population genetics, Population Health Management, tagged , , , , , on December 22, 2019| Leave a Comment »

Diversity and Health Disparity Issues Need to be Addressed for GWAS and Precision Medicine Studies

Curator: Stephen J. Williams, PhD

 

 

From the POLICY FORUM ETHICS AND DIVERSITY Section of Science

Ethics of inclusion: Cultivate trust in precision medicine

 See all authors and affiliations

Science  07 Jun 2019:
Vol. 364, Issue 6444, pp. 941-942
DOI: 10.1126/science.aaw8299

Precision medicine is at a crossroads. Progress toward its central goal, to address persistent health inequities, will depend on enrolling populations in research that have been historically underrepresented, thus eliminating longstanding exclusions from such research (1). Yet the history of ethical violations related to protocols for inclusion in biomedical research, as well as the continued misuse of research results (such as white nationalists looking to genetic ancestry to support claims of racial superiority), continue to engender mistrust among these populations (2). For precision medicine research (PMR) to achieve its goal, all people must believe that there is value in providing information about themselves and their families, and that their participation will translate into equitable distribution of benefits. This requires an ethics of inclusion that considers what constitutes inclusive practices in PMR, what goals and values are being furthered through efforts to enhance diversity, and who participates in adjudicating these questions. The early stages of PMR offer a critical window in which to intervene before research practices and their consequences become locked in (3).

Initiatives such as the All of Us program have set out to collect and analyze health information and biological samples from millions of people (1). At the same time, questions of trust in biomedical research persist. For example, although the recent assertions of white nationalists were eventually denounced by the American Society of Human Genetics (4), the misuse of ancestry testing may have already undermined public trust in genetic research.

There are also infamous failures in research that included historically underrepresented groups, including practices of deceit, as in the Tuskegee Syphilis Study, or the misuse of samples, as with the Havasupai tribe (5). Many people who are being asked to give their data and samples for PMR must not only reconcile such past research abuses, but also weigh future risks of potential misuse of their data.

To help assuage these concerns, ongoing PMR studies should open themselves up to research, conducted by social scientists and ethicists, that examines how their approaches enhance diversity and inclusion. Empirical studies are needed to account for how diversity is conceptualized and how goals of inclusion are operationalized throughout the life course of PMR studies. This is not limited to selection and recruitment of populations but extends to efforts to engage participants and communities, through data collection and measurement, and interpretations and applications of study findings. A commitment to transparency is an important step toward cultivating public trust in PMR’s mission and practices.

From Inclusion to Inclusive

The lack of diverse representation in precision medicine and other biomedical research is a well-known problem. For example, rare genetic variants may be overlooked—or their association with common, complex diseases can be misinterpreted—as a result of sampling bias in genetics research (6). Concentrating research efforts on samples with largely European ancestry has limited the ability of scientists to make generalizable inferences about the relationships among genes, lifestyle, environmental exposures, and disease risks, and thereby threatens the equitable translation of PMR for broad public health benefit (7).

However, recruiting for diverse research participation alone is not enough. As with any push for “diversity,” related questions arise about how to describe, define, measure, compare, and explain inferred similarities and differences among individuals and groups (8). In the face of ambivalence about how to represent population variation, there is ample evidence that researchers resort to using definitions of diversity that are heterogeneous, inconsistent, and sometimes competing (9). Varying approaches are not inherently problematic; depending on the scientific question, some measures may be more theoretically justified than others and, in many cases, a combination of measures can be leveraged to offer greater insight (10). For example, studies have shown that American adults who do not self-identify as white report better mental and physical health if they think others perceive them as white (11, 12).

The benefit of using multiple measures of race and ancestry also extends to genetic studies. In a study of hypertension in Puerto Rico, not only did classifications based on skin color and socioeconomic status better predict blood pressure than genetic ancestry, the inclusion of these sociocultural measures also revealed an association between a genetic polymorphism and hypertension that was otherwise hidden (13). Thus, practices that allow for a diversity of measurement approaches, when accompanied by a commitment to transparency about the rationales for chosen approaches, are likely to benefit PMR research more than striving for a single gold standard that would apply across all studies. These definitional and measurement issues are not merely semantic. They also are socially consequential to broader perceptions of PMR research and the potential to achieve its goals of inclusion.

Study Practices, Improve Outcomes

Given the uncertainty and complexities of the current, early phase of PMR, the time is ripe for empirical studies that enable assessment and modulation of research practices and scientific priorities in light of their social and ethical implications. Studying ongoing scientific practices in real time can help to anticipate unintended consequences that would limit researchers’ ability to meet diversity recruitment goals, address both social and biological causes of health disparities, and distribute the benefits of PMR equitably. We suggest at least two areas for empirical attention and potential intervention.

First, we need to understand how “upstream” decisions about how to characterize study populations and exposures influence “downstream” research findings of what are deemed causal factors. For example, when precision medicine researchers rely on self-identification with U.S. Census categories to characterize race and ethnicity, this tends to circumscribe their investigation of potential gene-environment interactions that may affect health. The convenience and routine nature of Census categories seemed to lead scientists to infer that the reasons for differences among groups were self-evident and required no additional exploration (9). The ripple effects of initial study design decisions go beyond issues of recruitment to shape other facets of research across the life course of a project, from community engagement and the return of results to the interpretation of study findings for human health.

Second, PMR studies are situated within an ecosystem of funding agencies, regulatory bodies, disciplines, and other scholars. This partly explains the use of varied terminology, different conceptual understandings and interpretations of research questions, and heterogeneous goals for inclusion. It also makes it important to explore how expectations related to funding and regulation influence research definitions of diversity and benchmarks for inclusion.

For example, who defines a diverse study population, and how might those definitions vary across different institutional actors? Who determines the metrics that constitute successful inclusion, and why? Within a research consortium, how are expectations for data sharing and harmonization reconciled with individual studies’ goals for recruitment and analysis? In complex research fields that include multiple investigators, organizations, and agendas, how are heterogeneous, perhaps even competing, priorities negotiated? To date, no studies have addressed these questions or investigated how decisions facilitate, or compromise, goals of diversity and inclusion.

The life course of individual studies and the ecosystems in which they reside cannot be easily separated and therefore must be studied in parallel to understand how meanings of diversity are shaped and how goals of inclusion are pursued. Empirically “studying the studies” will also be instrumental in creating mechanisms for transparency about how PMR is conducted and how trade-offs among competing goals are resolved. Establishing open lines of inquiry that study upstream practices may allow researchers to anticipate and address downstream decisions about how results can be interpreted and should be communicated, with a particular eye toward the consequences for communities recruited to augment diversity. Understanding how scientists negotiate the challenges and barriers to achieving diversity that go beyond fulfilling recruitment numbers is a critical step toward promoting meaningful inclusion in PMR.

Transparent Reflection, Cultivation of Trust

Emerging research on public perceptions of PMR suggests that although there is general support, questions of trust loom large. What we learn from studies that examine on-the-ground approaches aimed at enhancing diversity and inclusion, and how the research community reflects and responds with improvements in practices as needed, will play a key role in building a culture of openness that is critical for cultivating public trust.

Cultivating long-term, trusting relationships with participants underrepresented in biomedical research has been linked to a broad range of research practices. Some of these include the willingness of researchers to (i) address the effect of history and experience on marginalized groups’ trust in researchers and clinicians; (ii) engage concerns about potential group harms and risks of stigmatization and discrimination; (iii) develop relationships with participants and communities that are characterized by transparency, clear communication, and mutual commitment; and (iv) integrate participants’ values and expectations of responsible oversight beyond initial informed consent (14). These findings underscore the importance of multidisciplinary teams that include social scientists, ethicists, and policy-makers, who can identify and help to implement practices that respect the histories and concerns of diverse publics.

A commitment to an ethics of inclusion begins with a recognition that risks from the misuse of genetic and biomedical research are unevenly distributed. History makes plain that a multitude of research practices ranging from unnecessarily limited study populations and taken-for-granted data collection procedures to analytic and interpretive missteps can unintentionally bolster claims of racial superiority or inferiority and provoke group harm (15). Sustained commitment to transparency about the goals, limits, and potential uses of research is key to further cultivating trust and building long-term research relationships with populations underrepresented in biomedical studies.

As calls for increasing diversity and inclusion in PMR grow, funding and organizational pathways must be developed that integrate empirical studies of scientific practices and their rationales to determine how goals of inclusion and equity are being addressed and to identify where reform is required. In-depth, multidisciplinary empirical investigations of how diversity is defined, operationalized, and implemented can provide important insights and lessons learned for guiding emerging science, and in so doing, meet our ethical obligations to ensure transparency and meaningful inclusion.

References and Notes

  1. ↵
  2. ↵
  3. ↵
  4. ↵
  5. ↵
  6. ↵
  7. ↵
  8. ↵
  9. ↵
  10. ↵
  11. ↵
  12. C. P. Jones et al Ethn. Dis. 18, 496 (2008).
  13. C. C. Gravlee, A. L. Non, C. J. Mulligan
  14. S. A. Kraft et al Am. J. Bioeth. 18, 3 (2018).
  15. A. E. Shields et al Am. Psychol. 60, 77 (2005).
    CrossRefPubMedWeb of ScienceGoogle Scholar

Read Full Post »

Bioinformatic Tools For RNASeq: A Curation

Posted in Cancer - General, Cell Biology, Computational Biology/Systems and Bioinformatics, CRISPR alternative for editing genes without cutting, CRISPR/Cas9 & Gene Editing, Disease Biology, Meta-analysis of transcriptome data, RNA Biology, RNA Biology, Cancer and Therapeutics, tagged , , , , , , , on December 18, 2019| Leave a Comment »

Bioinformatic Tools for RNASeq: A Curation

Curator: Stephen J. Williams, Ph.D. 

 

 

Note:  This will be an ongoing curation as new information and tools become available.

RNASeq is a powerful tool for the analysis of the transcriptome profile and has been used to determine the transcriptional changes occurring upon stimuli such as drug treatment or detecting transcript differences between biological sample cohorts such as tumor versus normal tissue.  Unlike its genomic companion, whole genome and whole exome sequencing, which analyzes the primary sequence of the genomic DNA, RNASeq analyzes the mRNA transcripts, thereby more closely resembling the ultimate translated proteome. In addition, RNASeq and transcriptome profiling can determine if splicing variants occur as well as determining the nonexomic sequences, such as miRNA and lncRNA species, all of which have shown pertinence in the etiology of many diseases, including cancer.

However, RNASeq, like other omic technologies, generates enormous big data sets, which requires multiple types of bioinformatic tools in order to correctly analyze the sequence reads, and to visualize and interpret the output data.  This post represents a curation by the RNA-Seq blog of such tools useful for RNASeq studies and lists and reviews published literature using these curated tools.

 

From the RNA-Seq Blog

List of RNA-Seq bioinformatics tools

Posted by: RNA-Seq Blog in Data Analysis, Web Tools September 16, 2015 6,251 Views

from: https://en.wiki2.org/wiki/List_of_RNA-Seq_bioinformatics_tools

A review of some of the literature using some of the aforementioned curated tools are discussed below:

 

A.   Tools Useful for Single Cell RNA-Seq Analysis

 

B.  Tools for RNA-Seq Analysis of the Sliceasome

 

C.  Tools Useful for RNA-Seq read assembly visualization

 

Other articles on RNA and Transcriptomics in this Open Access Journal Include:

NIH to Award Up to $12M to Fund DNA, RNA Sequencing Research: single-cell genomics, sample preparation, transcriptomics and epigenomics, and genome-wide functional analysis.

Single-cell Genomics: Directions in Computational and Systems Biology – Contributions of Prof. Aviv Regev @Broad Institute of MIT and Harvard, Cochair, the Human Cell Atlas Organizing Committee with Sarah Teichmann of the Wellcome Trust Sanger Institute

Complex rearrangements and oncogene amplification revealed by long-read DNA and RNA sequencing of a breast cancer cell line

Single-cell RNA-seq helps in finding intra-tumoral heterogeneity in pancreatic cancer

First challenge to make use of the new NCI Cloud Pilots – Somatic Mutation Challenge – RNA: Best algorithms for detecting all of the abnormal RNA molecules in a cancer cell

Evolution of the Human Cell Genome Biology Field of Gene Expression, Gene Regulation, Gene Regulatory Networks and Application of Machine Learning Algorithms in Large-Scale Biological Data Analysis

 

Read Full Post »

youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on December 17, 2019| Leave a Comment »

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is pleased to invite you to youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

First Round of VC Firms Announced

Second Virtual Summit to feature over 100 VCs

Friends,

We’re pleased to announce the first round of VCs confirmed to be featured at Venture Summit Virtual Connect | Global being held on August 4th – 6th, 2020.

This exclusive venture summit will bring together over 1,300 VCs, corporate VCs, angel investors, industry executives, and founders of venture-backed, emerging, and early-stage companies, will feature more than 100 leading VCs, presentations by 100 cutting-edge innovators, and high-level networking opportunities.

Register Now to lock in the lowest rates possible. Click here

Submit your company for the opportunity to present to leading investors: Click here

 

Connect with leading early stage VCs

 

Susan Akbarpour

Partner

Candou Ventures

Sep Alavi

Venture Partner

White Star Capital

Grant Allen

General Partner

Schneider Electric Ventures

Logan Allin

General Partner

Fin Venture Capital

Milad Alucozai

Partner

Good AI Capital

Amolak Badesha

Investor

Sand Hill Angels

Wade Bitaraf

Founder, Energy & Sustainability

Plug & Play Tech Center

Greg Bohlen

Managing Director

Union Grove Venture Partners

Christophe Bourque

General Partner

White Star Capital

Daniel Burstein

Managing Partner

Millennium Technology Value Partners

Adam Carson

Operating Partner

Point72 Ventures

Jeffrey Cherry

Co-Founder & Executive Director

Conscious Venture Lab

Elizabeth Cho-Fertikh

Cofounder & Managing Director

MEDA Angels

Andy Clapp

Managing Partner

Arctaris Capital Partners

Jay Crone

Director, Investments

TELUS Ventures

Lake Dai

Partner

LDV Partners

Angelo Del Priore

Partner

HP Tech Ventures

Jun Deng

Investment Partner

Joyance Partners

Robert Dunkle

Founder and CEO

ABES Venture Partners

Amy Dyck

Associate

Framework Venture Partners

Nick Efstratis

Managing Director

EPIC Ventures

Mark Farrell

Managing Director

Thayer Ventures

Andrew Felbinger

Investor

Urban Innovation Fund

Constance Freedman

Managing Partner

Moderne Ventures

Isabelle Freidheim

Managing Partner

Starwood VC

Stan Fung

Managing Director

FarSight Ventures

Norm Gitis

Managing Partner

Lymo Ventures

Ajay Gopal

Principal

Framework Venture Partners

Robert Hamlin

Principal

Portag3 Ventures

Florian Haupt

Partner

TruVenturo

Ben Jen

Investor

Ben Jen Holdings

Najib Khouri-Haddad

General Partner

Sway Ventures

Ryan Kole

Partner

VCapital

Elaine Kunda

Founder, Managing Director

Disruption Ventures

Eddie Lee

Principal

White Star Capital

James Lee

Director

Photon Fund Venture Capital

Jessica Li

Investor

Soma Capital

Ephraim Lindenbaum

Managing Director

Advance Ventures

Darwin Ling

Founding General Partner

Good AI Capital

Edwin Loredo

Vice President

Core Innovation Capital

Wasim Malik

Managing Partner

Iaso Ventures

Eugene Malobrodsky

Venture Partner

One Way Ventures

Eric Martineau-Fortin

Co-Founder and Managing Partner

White Star Capital

Philip Mertens

Associate

DSM Venturing

Ivan Nikkhoo

Managing Partner

Navigate Ventures

Carlos Ochoa

Managing Partner

AI8 VENTURES

Valerie Photos

Operating Partner

Iaso Ventures

Filipe Portela

Managing Partner

COREangels Atlantic

Safa Rashtchy

Managing Director

Think + Ventures

John Ricci

Managing Director

US Angels

Alex Rozenfeld

Managing Director

Climate Impact Capital

Gayatri Sarkar

Managing Partner

Hype Capital VC Fund

Brian Schuman

Investment Professional

PepsiCo Technology Ventures

Kristina Serafim

Managing Director

Verizon Ventures

Greg Shepard

Managing Partner

BOSS Capital Partners

Charles Sidman

Managing Partner

ECS Capital Partners

Sean Simpson

Director

WIND Ventures

Jean Sini

General Partner

Partech

Mark A. Solovy

Managing Director

Monroe Capital

Vivek Soni

General Partner

S Cap Cleantech Fund

Kat Utecht

Managing Partner

Core Innovation Capital

Jordan Wahbeh

Managing Partner

SV Venture Group

Henry Wong

Managing Partner

Diamond Tech Ventures

Stephanie Zepeda

Senior Associate

Arbor Ventures

We’re just getting started, more to be announced!

CALL FOR

TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

A select group of more than 100 Top Innovators from the fintech, technology, clean-tech, life sciences/healthcare, medical devices, healthcare IT, and mobile sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners!

First Round Submission Deadline for presenting company applications is TODAY June 11th, 2020.

To apply, your company must be privately held and ideally come from one of the following industry sectors:

Tech

Life Sciences / Healthcare

CleanTech

FinTech

EdTech

Hardware

Internet/Digital Media

IoT

Mobile

Security

Software/IT

Biotech

Diagnostics

Drug Discovery

Healthcare IT

Medical Devices

Pharma

Energy Efficiency

Energy Generation

Energy Infrastructure

Energy Storage

Transportation

Water & Wastewater

Banking

Blockchain

Insurtech

Personal Finance

Payments

Predictive Analytics

 

Questions about presenting? Email Preston Michaels at iwant2present (at) youngstartup .co

Seed Stage Track

If you are a seed-stage company seeking angel funding and would like to present check out our seed stage track.

If you’re seeking less than $1M (and have raised less than $300,000) this is for you.

Joe Benjamin

Founder & CEO

youngStartup Ventures

“Where Innovation Meets Capital”

Don’t hesitate to connect with me personally via LinkedIn and request to join our venture network LinkedIn group below.

August 4-6, 2020

  Contact

  youngstartup.com/vcglobal

  info@youngstartup.co  

   212.202.1002

@@@@@

Save 20% with discount code LPBI-VIP

NEW DATE

May 5 – 7, 2020

UPDATED on 4/21/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group invites you to join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5th– 7th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze  Register here today to confirm your spot: http://bit.ly/2PfsbM7  35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

Whether you are an investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.

 

Twitter

Join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5th– 7th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register here today to confirm your spot: http://bit.ly/2PfsbM7  35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

 

Where do #startups connect with leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit | Virtual Connect being held on May 5th– 7th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register at  http://bit.ly/2PfsbM7 and get 35% off with Discount Code: LPBI-VIP. #StayHomeSaveLives

  

Facebook

Leaders in Pharmaceutical Business Intelligence (LPBI) Group invites you to join leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect being held on May 5th– 7th 2020. One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynote by non-other than Uri Levine, co-founder of Waze. Register here today to confirm your spot: http://bit.ly/2PfsbM7  35%  off with Discount Code: LPBI-VIP. #StayHomeSaveLives

 

 

@@@@ 

Venture Summit \ Virtual Connect

Where Innovation Meets Capital

May 5 – 7, 2020

 

Join early stage VCs, Corporate VCs, Angel Investors and founders of venture backed, emerging and early stage companies at Venture Summit \ Virtual Connect on May 5-7 2020.

 

Whether you’re a startup seeking capital and exposure, or an investor seeking new deals, Venture Summit \ Virtual Connect is one event you won’t want to miss.

 

A highly productive venture conference, Venture Summit \ Virtual Connect will feature:

 

  • Over 100 VCs (regional and national)
  • Presentations by 100 Top Innovators
  • One-on-One (zoom) investor + startup meetings
  • 2 days of content including timely panel discussions and workshops
  • Keynote: Uri Levine, co-founder of Waze

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has made special arrangement for our network to receive 20% off with discount code LPBI-VIP (Note: Rates will go up this Thursday at midnight but the discount will still apply).

 

Register Today & Save Click here http://bit.ly/2PfsbM7.   

 

Over 100 Investors Confirmed:

11.2 Capital, 500 Startups, ABES Venture Partners, Activate Capital, Advance Ventures, Aligned Partners, Alliance of Angels, Alliance Ventures, Alpha Square Group, American Family Ventures, AMINO Capital, Anzu Partners, Arbor Ventures, ARIE Capital, Asset Management Ventures, Augment Ventures, Avestria Ventures, BAM Ventures, Band of Angels, Bay Angels, Bee Partners, Ben Jen Holdings, Benhamou Global Ventures, Better Ventures, Blue Bear Capital, Blue Bear Ventures, Blue Startups, BlueRun Ventures, Boehringer Ingelheim Venture Fund, Boeing HorizonX Ventures, Brand New Matter, Candou Ventures , Catapult VC, Charles River Ventures, CIG CAP, Citi Ventures, City Light Capital, Clean Energy Venture Group, Communitas Capital Partners, Core Innovation Capital, COREangels Atlantic, Costanoa Ventures, Cottonwood Technology Fund, CRCM Ventures, Crestlight Ventures, Data Collective, Deutsche Telekom Capital Partners, DHVC, DigitalDX Ventures, Disruption Ventures, Dow Ventures, DPH Ventures, DSM Venturing, DXA Investments, Dynamk Capital, E. ON , E8 Angels, ECS Capital Partners, Elevate Ventures, Energy Foundry, Energy Innovation Capital, ENGIE New Ventures, Eudemian Ventures, Evok Innovations, F-Prime Capital, Fidelity Investments, Financial Venture Studio, FinSight Ventures, Fort Ross Ventures, Foundation Capital, Framework Venture Partners, Galaxy Digital, Garage Technology Ventures, GM Ventures, Good AI Capital, Good Growth Capital, H.I.G. Growth Partners, Halogen Ventures, Harvard Business School Angels, HealthTech Capital, Henkel Ventures, HP Tech Ventures, Hype Capital VC Fund, Insight Partners, JetBlue Technology Ventures, Johnson & Johnson Innovation – JJDC, Journey Venture Partners, Joyance Partners, Juniper Networks, K5 Ventures, Kubera Venture Capital, Lam Capital, Life Science Angels, Lymo Ventures, Magnet Ventures, ManchesterStory Group, Marcy Venture Partners, McKesson Ventures, Mighty Capital, Millennium Technology Value Partners, Moderne Ventures, Morpheus Ventures, Munich Re Ventures, MVM Partners, National Science Foundation, Navigate Ventures, NEA, New Science Ventures, New York Life Ventures, NextGen Venture Partners, NextWorld Capital, Nielsen Innovate, OCA Ventures, One Way Ventures, Owl Ventures, Pangaea Ventures, Paypal Ventures, Photon Fund, Pipeline Angels, Plug & Play Tech Center, Point72 Ventures, Portag3 Ventures, Portfolia, Prelude Ventures, PROOF VC, Revel Partners, SABIC Ventures, Samsung Catalyst Fund, Sand Hill Angels, Santander InnoVentures, Saudi Angel Fund, Shasta Ventures, SignalFire, Social Impact Capital, Spike Ventures, Starwood VC, Sunrise Capital Partners, Sway Ventures, Tech Coast Angels, The Westly Group, TiE Angels, TruVenturo, UL Ventures, Union Grove Venture Partners, Unusual Ventures, US Angels, Verizon Ventures, Viridian Capital, VisionPassage, Volvo Cars Tech Fund, WAVE Equity Partners, Wharton Alumni Angels More to be announced.

 

More details: http://bit.ly/2PfsbM7

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group & youngStartup Ventures

 

OLD CONTENT

NEW DATE  Venture Summit | West – “Where Innovation Meets Capital”, May 5 – 7, 2020,

Santa Clara Convention Center, Silicon Valley

VSW20 – Discount code, LPBI-VIP and unique event site link http://bit.ly/2PfsbM7.

Video link for most recent event http://bit.ly/2LQpONN 

 

UPDATED on 3/25/2020

The dedicated discount code LPBI-VIP and unique event site link http://bit.ly/2PfsbM7 now entitles LPBI network to $350 off the current rates. Applicants should register as soon as possible to lock in the lowest possible rates.

We will be hosting 1on1 startup and investor meetings live at Venture Summit | West [digital edition] online in May. The summit will now be expanded for featured companies to 3 days, May 5th – 7th (coaching session + 2 days of content and one on one sessions) and for general attendees to 2 days.

The summit will feature over 150 venture funds as speakers/judges (many others in attendance), more than 100 Top Innovators as presenters, effective and seamless 1:1 meetings + chat, and high-level networking opportunities.

The screening committee is currently interviewing companies and will be selecting more than 100 Top Innovators to present live to the investors at the summit.

Featured Confirmed VC Speakers & Judges:

Kira Noodleman

Bee Partners

 

Kira enjoys tackling problems in disruptive industries and across cultures. Her appreciation for skillful risk-taking attracted her to entrepreneurship, and ultimately to her role in venture capital. At Bee Partners, she spends the majority of her time identifying and investing in Founders and startups servicing enterprises and enabling new marketplaces. She dedicate the remainder of […] Read more

Li Sun

Foundation Capital

 

Li Sun comes from a global background spanning four countries with diverse experiences across engineering, science, technology, and entrepreneurship. She holds a B.Eng in EE and business (1st class honors) from NTU in Singapore, an M.Eng in Materials Science from MIT, and a PhD in Applied Physics from Harvard. During her PhD, she cofounded and […] Read more

Bill Reichert

Garage Technology Ventures

 

Bill Reichert is co-founder and Managing Director of Garage Technology Ventures, a seed and early stage venture capital firm based in Silicon Valley. He is also a Partner at Pegasus Tech Ventures, a global venture capital firm with offices in Silicon Valley and around the world. Bill and his partners invest in promising emerging technology […] Read more

Charlie Hanna

Marcy Venture Partners

 

Charlie Hanna is an investor at Marcy Venture Partners (MVP) in San Francisco, an early-stage venture capital firm co-founded by Larry Marcus, Jay Brown and Jay-Z. Charlie’s focus is consumer products and services with an emphasis on sustainability, accessibility and culture. Prior to MVP, Charlie was an Associate at SWAT Equity Partners, a NYC-based venture […] Read more

SC Moatti

Mighty Capital

 

SC Moatti is the managing partner of Mighty Capital, a Silicon Valley venture capital firm, and Products That Count, one of the largest communities of product managers, leaders and entrepreneurs in the world. Previously, she built products that billions of people use at Facebook, Nokia and Electronic Arts. She also serves on boards of both […] Read more

Mario Ruiz

Paypal Ventures

 

Mario Ruiz is a financial technology investor at PayPal Ventures, focusing on investments in the U.S. and internationally. Prior to joining PayPal, Mario was an investor at Napier Park, where he was a member of a nine-person investment team responsible for the evaluation, diligence, and execution of growth equity and real asset investments. Mario started […] Read more

Danny Cotter

The Westly Group

 

Danny Cotter serves as Principal at The Westly Group. Prior to joining the Westly Group, He worked at Pacific Gas & Electric Company where he focused on discovering advanced technology pilots and analyzing regulatory, competitive and technology landscapes to shape smart grid strategies across the organization. While at PG&E, He also helped lead the development […] Read more

 

UPDATED on 2/26/2020

The dedicated discount code LPBI-VIP and unique event site link http://bit.ly/2PfsbM7 now entitles LPBI network to $350 off the current rates. Applicants should register as soon as possible to lock in the lowest possible rates.

Updated list of over 130 VCs and Angels confirmed to speak and judge. 

 

Partial Lineup of over 130 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Andrew Abrams, Vice President, New Science Ventures | Susan Akbarpour, Partner, Candou Ventures | Joel Albarella, Founder, New York Life Ventures | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Shaun Arora, Founding Partner, MiLA Capital | Doug Atkin, Managing Partner, Communitas Capital Partners | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Mike Biddle, Managing Director, Evok Innovations | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Dave Blivin, Managing Director, Cottonwood Technology Fund | Greg Bohlen, Managing Director, Union Grove Venture Partners | Maureen Boyce, Managing Partner, Good Growth Capital | Peter Bruce-Clark, Partner, Social Impact Capital | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Amy Burr, Managing Director, JetBlue Technology Ventures | Ray Chan, Managing Director, K5 Ventures | Ryan Chou, Investment Associate, JetBlue Technology Ventures | Darren Cooke, Investor, Life Science Angels | Martha Cosgrove, Investing Associate, Boeing HorizonX | Danny Cotter, Principal, The Westly Group | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Ted Driscoll, Managing Partner, DigitalDX Ventures | Robert Dunkle, President, ABES Venture Partners | Ali Farahanchi, Director, DHVC | Anna Fokina, Senior Associate, Data Collective | Isabelle Freidheim, Co-founder & Managing Partner, Starwood VC | Emily Fritze, Senior Associate, The Westly Group | Will Fung, Senior Associate, Samsung Catalyst Fund | Norm Gitis, Managing Partner, Lymo Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Daniel Greene, Principal, Wipro Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Florian Haupt, Partner, TruVenturo | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Michael Julve, Associate, 500 Startups | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Shruti Kothari, Director, Kaiser Permanente Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Marina Levinson, Partner, Benhamou Global Ventures | Larry Li, Managing Partner, AMINO Capital | Darwin Ling, Founding General Partner, Good AI Capital | Catherine Lu, Managing Partner , Alumni Ventures Group (AVG) | Vincent Lui, Partner, XCEL Asia | Hector MacQuarrie, Senior Investment Associate, Shell Ventures | Radhika Malik, Investment Manager, Samsung Catalyst Fund | Ricky Margolis, VP of Business Development, ARIE Capital | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | Eric Meyer, Vice President, Activate Capital | Jonathan Mo, Senior Associate, 11.2 Capital | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Maxim Nazarov, Investor, FinSight Ventures | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Brett Noyes, Founder & Managing Director, Unbank. Ventures | Demi Obayomi, Investor, NextWorld Capital | Nihar Patel, General Partner, Journey Venture Partners | Charles Paul, Vice President – Technology, Henkel Ventures | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Scott Pinizzotto, Senior Investment Director, ENGIE New Ventures | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Jordan Segall, Enterprise Investor, Unusual Ventures | Kristina Serafim, Managing Director, Verizon Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Sean Simpson, Investment Manager, GM Ventures | Ratan Singh, Principal, Fort Ross Ventures | Kenn So, Associate, Shasta Ventures | Allison Steitz, Investor, BlueRun Ventures | Li Sun, Partner, Foundation Capital | Jessica Tan, Associate, 500 Startups | Grahme Taylor, Venture Analyst, Wildcat Venture Partners | Jonathan Tower, Founding Managing Partner, Catapult VC | Erica Van, Investor, Charles River Ventures | Anuj Varma, Investor, BAM Ventures | Kutral Veerabadran, Principal, Flow Capital | Alessandro Vigilante, Head of Global Innovation Ecosystem, Fidelity Investments | Sonali Vijayavargiya, Managing Director, Augment Ventures | Alex Whitney, Senior Analyst, ManchesterStory Group | Henry Wong, Managing Director, Garage Technology Ventures | Joanne Wong, General Partner, REDDS Capital | Russell Yue, Investor, H.I.G. Growth Partners | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more…

 

 

UPDATED on 2/6/2020

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to spons and invite you to join us at Venture Summit | West

Special offer:  Register Now & Save $450 off (Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23rd & 24th  2020

Santa Clara Convention Center, Silicon Valley

 

Reminder to register for the prestigious Venture Summit | West being held on March 23rd & 24th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track. Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies.

 

Whether you’re a Lifesciences/Healthcare startup seeking capital and exposure, or an investor seeking new deals, Venture Summit West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 

Partial Initial Lineup of over 90 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Andrew Abrams, Vice President, New Science Ventures | Susan Akbarpour, Partner, Candou Ventures | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Shaun Arora, Founding Partner, MiLA Capital | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Dave Blivin, Managing Director, Cottonwood Technology Fund | Greg Bohlen, Managing Director, Union Grove Venture Partners | Maureen Boyce, Managing Partner, Good Growth Capital | Peter Bruce-Clark, Partner, Social Impact Capital | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Darren Cooke, Investor, Life Science Angels | Martha Cosgrove, Investing Associate, Boeing HorizonX | Danny Cotter, Principal, Westly Group | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Robert Dunkle, President, ABES Venture Partners | Ali Farahanchi, Director, DHVC | Anna Fokina, Senior Associate, Data Collective | Norm Gitis, Managing Partner, Lymo Ventures | Daniel Greene, Principal, Wipro Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Florian Haupt, Partner, TruVenturo | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Shruti Kothari, Director, Kaiser Permanente Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Marina Levinson, Partner, Benhamou Global Ventures | Larry Li, Managing Partner, AMINO Capital | Darwin Ling, Founding General Partner, Good AI Capital | Catherine Lu, Managing Partner , Alumni Ventures Group (AVG) | Vincent Lui, Partner, XCEL Asia | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | Eric Meyer, Vice President, Activate Capital | Jonathan Mo, Senior Associate, 11.2 Capital | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Brett Noyes, Founder & Managing Director, Unbank.Ventures | Charles Paul, Vice President – Technology, Henkel Ventures | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Scott Pinizzotto, Senior Investment Director, ENGIE New Ventures | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Kristina Serafim, Managing Director, Verizon Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Principal, Fort Ross Ventures | Allison Steitz, Investor, BlueRun Ventures | Li Sun, Partner, Foundation Capital | Grahme Taylor, Venture Analyst, Wildcat Venture Partners | Jonathan Tower, Founding Managing Partner, Catapult VC | Erica Van, Investor, Charles River Ventures | Anuj Varma, Investor, BAM Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Alex Whitney, Senior Analyst, ManchesterStory Group | Henry Wong, Managing Director, Garage Technology Ventures | Russell Yue, Investor, H.I.G. Growth Partners | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more.

 

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

 

Register Today & Save Click here.   (Use promo code “ LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

Volunteer Opportunities:

Students and recent alumni are to volunteer to help out for part of the day and enjoy the summit for the other part. Volunteers assist with setup, registration, program coordination, company presentations etc. To join us as a volunteer, please fill out the form here: Click Here http://bit.ly/VSW20VOLUNTEER .

 

 

UPDATED on 1/16/2020

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to sponsor and invite you to join us at Venture Summit | West

Special offer:  Register Now & Save $450 off (Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23rd & 24th  2020

Santa Clara Convention Center, Silicon Valley

  

Reminder to register for the prestigious Venture Summit | West being held on March 23rd & 24th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track. Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies.

 

Whether you’re a Lifesciences/Healthcare startup seeking capital and exposure, or an investor seeking new deals, Venture Summit West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 

Partial Initial Lineup of over 60 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Shaun Arora, Founding Partner, MiLA Capital | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Greg Bohlen, Managing Director, Union Grove Venture Partners | Peter Bruce-Clark, Partner, Social Impact Capital | Darren Cooke, Investor, Life Science Angels | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Jun Deng, Partner, Joyance Partners | Robert Dunkle, President, ABES Venture Partners | Anna Fokina, Senior Associate, Data Collective | Norm Gitis, Managing Partner, Lymo Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Darwin Ling, Founding General Partner, Good AI Capital | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Principal, Fort Ross Ventures | Li Sun, Partner, Foundation Capital | Erica Van, Investor, Charles River Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more.

 

 

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off. This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   (Use promo code “ LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

 We look forward to seeing you there. 

 

LPBI & youngStartup Ventures

 

 @@@@@@

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to announce its sponsorship and invite you to join us at Venture Summit | West

Special offer:  Register Now & Save $450 off

(Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23rd & 24th  2020

Santa Clara Convention Center, Silicon Valley

  

Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit | West being held on March 23rd & 24th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track.

 

Whether you’re a Lifesciences/Healthcare startup seeking capital and exposure, or an investor seeking new deals, Venture Summit West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 

Lineup of over 150 VCs and Angels that spoke and judged at VSW19 includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Logan Allin, General Partner & Founder, Fin Venture Capital | Kareem Aly, Principal, Thomvest Ventures | Magdi Amin, Investment Partner, Omidyar Network | Ash Archibald, Deal Principal, Wharton Angels | Jennifer Azapian, Partner , Mighty Capital | Carlos S. Baradello, General Partner, Alaya Capital Partners | Scott Beechuk, Partner, Norwest Venture Partners | Marcus Behrendt, Partner, BMW i Ventures | Lisha Bell, Dealflow Lead, Pipeline Angels | Ashish Bhatia, Angel Investor | Sunny Bia, Associate, CRCM Ventures | Mike Biddle, Managing Director, Evok Innovations | Alexa Binns, Associate, Maven Ventures | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Tico Blumenthal, Co-chair of the Medical Device Screening Committee, Life Science Angels | Greg Bohlen, Managing Director, Union Grove Venture Partners | Will Borthwick, Senior Associate, Bold Capital Partners | Eric Breese, Investment Manager, Evonik Venture Capital | Maxx Bricklin, Founding Principal, Bold Capital Partners | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Edouard Bulteau, Investment Manager, Total Energy Ventures | Andy Cao, Principal, Comcast Ventures | Packey Carrier, Investment Manager, American Express Ventures | Jeffrey Carter, General Partner, West Loop Ventures | Matthew Chavez, Associate, New Enterprise Associates | Joy Chen, Chief Investment Officer, TAL Education Group | Kelly Chen, Principal, Data Collective | Keting Chu, Venture Partner, LYFE Capital | Jackson Cummings, Investor, Salesforce Ventures | Michael D’Aurizio, Investment Manager, Centrica Innovations | Ned Daoro, Senior Associate, Clocktower Technology Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Rexhi Dollaku, Principal, Base10 | Yizhen Dong, Principal, 11.2 Capital | Ted Driscoll, Managing Partner, DigitalDX Ventures | Marah Dudenhoeffer, Manager, Verizon Ventures | Susannah Duke, Associate, Pelion Venture Partners | Robert Dunkle, President, ABES Venture Partners | Victor Echevarria, Principal, Jackson Square Ventures | Tom Eggleston, Managing Director , Charmides Capital | Geoffrey Eisenberg, Principal, Ecosystem Integrity Fund | Sean Engel, Principal, Top Tier Capital Partners | Michael Fanfant, Senior Associate, Runa Capital | Chenoa Farnsworth, Managing Director, Blue Startups | Kristen Faulkner, Associate, Threshold Ventures | Linda Fingerle, Partner, Tappan Hill Ventures | Spencer Foust, Principal, Sozo Ventures | Ben Freeberg, Senior Associate, Alpha Venture Partners | Chris Gaertner, Principal, Omega Venture Partners | Karim Gillani, General Partner, Luge Capital | Norm Gitis, Managing Partner, Life Science Angels | Garrett Goldberg, Partner, Bee Partners | Jocelyn Goldfein, Managing Director, Zetta Venture Partners | Daniel Gomez, Investment Analyst, Fusion Fund | Tyler Griffin, Managing Partner, Financial Venture Studio | Baris Guzel, Principal, BMW i Ventures | Perry Ha, Analyst, The Westly Group | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Daniel Harris, Managing Director, DPH Ventures | Laurence Hayward, Partner, Independence Equity | Annie Hazlehurst, Founder, Faridan | Alicia Castillo Holley, Investor, Sand Hill Angels | Jens Horstmann, Founding Director, Crestlight Ventures | Heyu Huang, Venture Partner, Fresco Capital | Anup Jacob, Co-Founder & Managing Director, Activate Capital Partners | Alexis Ji, Partner, Illumina Ventures | Gary Jinks, Founding Managing Director, South Valley Angels | Matt Jones, Managing Director, Solvay Ventures | Kathleen Jurman, Corporate Technology Scout, Dow Ventures | Amir Kabir, Investment Principal, Munich Re Ventures | Jimmy Kan, Senior Associate, Anzu Partners | Kester Keating, Head of US Strategic Investments, Barclays | Roger King, Founder, Bay Angels | Steve Kishi, Managing Director, Hummer Winblad Venture Partners | Yasemin Kliman, Co-President, Harvard Business School Angels | Daniella Kranjac, Co-Founder & Managing Director, Dynamk Capital | Nathan Krishnamurthy, Principal, Capital One Growth Ventures | Vivek Krishnamurthy, Associate, Commerce Ventures | Amit Kumar, Investor, Band of Angels | Kwasi Kyei, Associate, Sandbox Industries | Eduardo Laiter, Sr Investment Analyst, Kapor Capital | Severine Lalande, Investment Manager, Total Energy Ventures | Javaughn Lawrence, Investor, Eniac Ventures | Lindsay Lee, Managing Director, Authentic Ventures | Roberta Lee, Angel Investor, Life Science Angels | Sarah Lee, Investor, EdVentures Group | Julie Lein, Managing Partner, Urban Innovation Fund | Geraldine Le Meur, Founding Partner, The Refiners | Ephraim Lindenbaum, Managing Director, Advance Ventures | Alex Luce, Principal, Creative Ventures | Vincent Lui, Senior Director of Corporate Ventures, SK Telecom Americas | Silvia Mah, Executive Director and Founder, Hera Angels | Ashish Mahashabde, Investor, Amex Ventures | Shripriya Mahesh, Co-Founding Partner, Spero Ventures | Tasneem Manjra, Head of Network Development, Volvo Cars Tech Fund | Jillian Manus, Managing Partner, Structure Capital | Ben Metcalfe, Principal, Ridge Ventures | Wouter Meuleman, Director of Investments, Illumina Ventures | SC Moatti, Managing Partner, Mighty Capital | Linda Molnar, Program Director, National Science Foundation | Sasha Ostojic, Angel investor, Playground Global | Umesh Padval, Venture Partner, Thomvest Ventures | Hirak Parikh, Venture Partner, Augment Ventures | Victor Pascucci III, Managing Partner, Lightbank | Phoebe Peronto, Investor, Salesforce Ventures | Ricardo Politi, Partner, Mindset Ventures | Salil Pradhan, Venture Partner, Draper Nexus | Gagan Rana, Executive-in-Residence, Learn Capital | Peter Redford, Investor, Band of Angels | Bill Reichert, Managing Director, Garage Technology Ventures | John Ricci, Founder & Managing Partner, US Angels | Jennifer Richard, Senior Associate, Cross Culture Ventures | Andre Rocha, Investor, Glasswing Ventures | Riley Rodgers, Associate, Valia Investments | Peter Rojas, Founding Partner, Betaworks Ventures | Praveen Sahay, Managing Director, WAVE Equity Partners | Natalie Sandman, Senior Associate, Shasta Ventures | Miraj Sanghvi, Principal, DigiTx | Jason Schoettler, Co-Founder & Partner, Calibrate Ventures | Wes Selke, Managing Director, Better Ventures | Jayni Shah, Principal, Accomplice | Prashant Shah, Partner, Monta Vista Capita | Ann Shin, Founding Partner, Ultrafund Capital | Charles Sidman, Managing Partner, ECS Capital Partners | Kathleen Siswanto, Investor, Propel Venture Partners | Ira Smith, Director of Venture Investments, Pandect BioVentures | Tanya Soman, Venture Partner, 500 Startups | Shirley Speakman, Partner, Cycle Capital Management | Adam Spector, Angel Investor | Kumar Sripadam, Chair, TiE Global | Jack Statza, Senior Associate, Allstate Strategic Ventures | George Straschnov, Managing Director, Bisk Ventures | Marcus Stroud, Managing Partner, TXV Partners | Mayra Tama, Principal, Initial Capital | Wei Tao, Life Science Angels, Chair Bio Genomics Committee | Craig Taylor, General Partner, Alloy Ventures | Laura Thompson, Principal, Sapphire Ventures | Vishal Verma, General Partner, Edgewood Ventures | Che Voigt, Chairman, North Bay Angels | Jordan Wahbeh, Managing Director, Bay Angels | Timothy Wang, Principal, The Westly Group | Kyoko Watanabe, Managing Director, DEFTA Partners | Patricia Wexler, Co-Founder & Managing Director, Starlight Ventures | James Wu, Senior Associate, M12 | Jonathan Wu, Board Director and Vice President, Sand Hill Angels | Margaret Wu, Investor, Georgian Partners | Veronica Wu, Managing Partner, Hone Capital | Wei Wu, Healthcare Investment Director, BOE Ventures | Matthew Wukasch, Managing Director, Charmides Capital | Wenz Xing, Associate, Bullpen Capital | Sue Xu, Managing Partner , Amino Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Jimmy Zhu, Vice President, Citi Ventures | Shelley Zhuang, Founder and Managing Partner, 11.2 Capital | TX Zhuo, Managing Partner, Fika Ventures and many more.

 

 

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   (Use promo code “ LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

  • Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

  • Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

 We look forward to seeing you there. 

 

LPBI & youngStartup Ventures

 

LPBI Group – Executive Summary

The Challenge

“Today, there is a digital information explosion in the fields of Life Sciences and Medicine,” said Aviva Lev-Ari, Ph.D., R.N., and founder of Leaders in Pharmaceutical Business Intelligence (LPBI) Group. “To manage that challenge, we are responding to the needs of our multi-faceted audiences in order to guard against information obsolescence through transformational technologies and solutions.”

 

Our Vision:

LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible.

 

About LPBI Group

Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, electronic scientific content-creation venture, offering real-time, original scientific content through advanced platform architecture methodologies since 2012. The company’s commitment is to synthesize, analyze and interpret complex, medical and scientific disease information through electronic publishing venues via the cloud to advance the knowledge and research efforts of the scientific and business community.

LPBI Group was created in 2012 by Dr. Aviva Lev-Ari, Ph.D., R.N. The Group has evolved into three, interrelated domains – an open-access online scientific journal, a series of 16 BioMed e-books and real-time press coverage of BioMed scientific and medical conferences. Through this transformative offering, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any subject as well as cutting-edge biomedical research innovation widely available to the scientific and non-research community. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Year over year, there is increased readership of highly valued content, which equates to more than 5,500 scientific articles with over 1.6 million readers in the online scientific journal.

 

Unique, Experienced Team

The Group employs a team of highly experienced individuals in Life Sciences, particularly within the key domains of BioMedicine, Biotechnology, Pharmaco-therapy, Medical and Information Technology, Health Care and the Life Sciences/Medicine connection.

All members of the LPBI Group team have a wealth of expertise and experience in Life Sciences and have been trained to master the methodology of scientific curation used in the articles. Those individuals include senior MDs, MD/PhDs, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes.

  • Medical Doctors: Dr. Larry H. Bernstein (retired), Dr. Justin Pearlman (Central Maine Medical Center)
  • Doctors of Philosophy: Dr. Justin Pearlman, Dr. Stephen Williams, Dr. Sudipta Saha, Dr. Ritu Saxena, Dr. Tilda Barliya, Dr. Irina Robu, Dr. Dror Nir, Dr. Aviva Lev-Ari
  • Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada), Adam Sonnenberg, PhD(c), Boston University
  • Executives in Biotechnology and Information Technology Industries: Amnon Danzig, MBA, Europe-Asia (business development consultant with specialization in Strategy, Corporate Finance and Human Capital, published author on Value Creation concepts), Rick Mandahl, MBA, Americas (business development consultant in emerging technologies with Biotech, Information Technology focus), Ritu Saxena (Astellas Pharma), Gail S. Thornton, M.A., PhD(c), (Merck & Co., USA, communications consultant, published author on health, wellness, communications strategy)

 

Scientific e-Books Source

The 16 BioMed e-books include topics focused on medical science, diagnostics and therapy. The books’ sustainability is maintained by online continuing updates made to articles in the online scientific journal. Each of the scientific e-books contain an abbreviated electronic table of contents, which consists of ‘live’ links from each article in the e-book to the article in the online scientific journal. Readers of the e-books can click on this link to receive the most, updated “State of Science” for each topic. This unique feature makes the e-books relevant and provides a timely source of knowledge and reference.

Highly qualified content consultants, who are senior MDs, MD/PhDs and Professors, are involved in the production and clinical interpretations of the curations. The topics for curation and the contents of the books are uniquely created and carefully edited. Dr. Aviva Lev-Ari as the editor-in-chief leads this multidisciplinary content compilation using her diverse areas of technical training and experience. It should be noted that all of LPBI’s material could, in principle, be translated into other languages.

 

Journal Ontology

Our intellectual property consists of three classes of Intellectual property assets as described in detail with live links in the following article:

eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/

 

Three Classes of Intellectual Property Assets

These assets include an open-access online scientific journal with curated, current biomedical research; a series of 16 BioMed e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomic Medicine (a subset of Precision Medicine), Cancer, Immunology and Precision Medicine; and real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in one click operation.

For example, Genomic Medicine, as an emerging medical discipline, is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases and infectious disease. This field involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.

The open-access online scientific journal ontology is a relational and hierarchical knowledge base allowing for expansion of the content creation process between the journal and the series of BioMed e-books, but it is not limited to these two areas. For example, one of the research categories, entitled “Interviews with Scientific Leaders,” includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component used extensively in the BioMed e-Series.

The Group’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. In our seven years together, the Group’s writers and editors generated a remarkable synergy among experts, authors and writers, which yields outstanding collaboration in producing these curations. There are many post-doctoral individuals in the biotechnology industry as well as academia who can serve as experts, authors and writers in continuing the Group’s operations, following appropriate onboarding.

Contact us

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, NJ, Salt Lake City, Berkeley, Cambridge UK, Maine, New Delhi, Palo Alto, Philadelphia, Toronto

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

Read Full Post »

Artificial Intelligence Innovations in Cardiac Imaging

Posted in AI-assisted Cardiac MRI, Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Artificial intelligence applications for cardiology, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care - Tools & Innovations, Artificial Intelligence in Medicine - Application for Diagnosis, Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI), Image Processing/Computing, Medical Imaging Technology, Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound, MRI, Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT, Ultra Sound on December 17, 2019| Leave a Comment »

Artificial Intelligence Innovations in Cardiac Imaging

Reporter: Aviva Lev-Ari, PhD, RN

3.3.23

3.3.23   Artificial Intelligence Innovations in Cardiac Imaging, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

‘CTA-for-All’ fast-tracks intervention, improves LVO detection in stroke patients

Anicka Slachta | November 15, 2019 | Cardiovascular Imaging

A “CTA-for-All” stroke imaging policy improved large vessel occlusion (LVO) detection, fast-tracked intervention and improved outcomes in a recent study of patients with acute ischemic stroke (AIS), researchers reported in Stroke.

“Combined noncontrast computed tomography (NCCT) and CT angiography (CTA) have been championed as the new minimum standard for initial imaging of disabling stroke,” Mayer, a neurologist at Henry Ford Hospital in Detroit, and co-authors wrote in their paper. “Patient selection criteria that impose arbitrary limits on time from last known well (LKW) or baseline National Institutes of Health Stroke Scale (NIHSS) score may delay CTA and the diagnosis of LVO.”

“These findings suggest that a uniform CTA-for-All imaging policy for stroke patients presenting within 24 hours is feasible and safe, improves LVO detection, speeds intervention and can improve outcomes,” the authors wrote. “The benefit appears to primarily affect patients presenting within six hours of symptom onset.”

SOURCE

https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/cta-all-fast-tracks-intervention-improves-lvo-detection-stroke?utm_source=newsletter&utm_medium=cvb_cardio_imaging

How to integrate AI into the cardiac imaging pipeline

Anicka Slachta | December 05, 2019 | Cardiovascular Imaging

Hsiao said physicians can expect “a little bit of generalization” from neural networks, meaning they’ll work okay on data that they’ve never seen, but they’re not going to produce perfect results the first time around. If a model was trained on 3T MRI data, for example, and someone inputs 1.5T MRI data, it might not be able to analyze that information comprehensively. If some 1.5T data were fed into the model’s training algorithm, though, that could change.

According to Hsiao, all of this knowledge means little without clinical validation. He said he and his colleagues are working to integrate algorithms into the clinical environment such that a radiologist could hit a button and AI could auto-prescribe a set of images. Even better, he said, would be the ability to open up a series and have it auto-prescribe itself.

“That’s where we’re moving next, so you don’t have to hit any buttons at all,” he said.

SOURCE

https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/how-integrate-ai-cardiac-imaging-pipeline?utm_source=newsletter&utm_medium=cvb_cardio_imaging

DiA Imaging, IBM pair to take the subjectivity out of cardiac image analysis

Anicka Slachta | December 05, 2019 | Cardiovascular Imaging

IBM Watson Health is adding startup DiA Imaging Analysis to its AI Marketplace in an effort to offer clinicians access to more objective and accurate ultrasound analysis, the company announced Dec. 1.

DiA, an IBM Alpha Zone Accelerator Alumni Startup, has developed AI-powered cardiac ultrasound software that’s already been cleared by the FDA. According to a release, the software was designed to help physicians analyze cardiac ultrasound images automatically and more objectively, since image interpretation is inherently a somewhat subjective process.

“Our collaboration with IBM Watson Health demonstrates the implementation of DiA’s vision to make the analysis of ultrasound images smarter and accessible to clinicians with various levels of experience on any platform,” DiA CEO and co-founder Hila Goldman-Aslan said in a statement.

IBM will focus specifically on DiA’s LVivo EF solution, an application with an AI-based quantification solution that provides clinicians with automated clinical data like ejection fraction and global longitudinal strain.

“IBM Watson Health is proud to announce a collaboration with DiA Imaging,” Anne Le Grand, general manager of imaging, life sciences and oncology at IBM, said. “DiA’s innovative AI-powered offerings can provide our clients with the ability to analyze images with advanced AI-based solutions which can support IBM Watson Health’s mission to help build smarter ecosystems.”

SOURCE

https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/dia-imaging-ibm-partner-cardiac-image-analysis?utm_source=newsletter&utm_medium=cvb_cardio_imaging

FDA clears Ultromics’ AI-based CV image analysis system

Anicka Slachta | November 18, 2019 | Cardiovascular Imaging

U.K.-based health tech firm Ultromics has secured 510(K) FDA clearance for its EchoGo Core image analysis system, the company announced Nov. 14.

EchoGo leverages artificial intelligence to calculate left ventricular ejection fraction, LV volumes and automated cardiac strain on ultrasound-based heart scans. The idea, founder and CEO Ross Upton said, is to automate the analysis and quantification of echos so cardiologists can make more informed decisions about care delivery.

“This is an incredibly exciting step toward the future of healthcare,” Upton, a Forbes “30 Under 30” honoree this year, said in a statement, calling the 510(K) clearance “truly a watershed moment” for his company.

Notably, the FDA’s choice to clear Ultromics’ technology means it will be available to a wider population of patients and providers. Based in the U.K., the company has only been independent of the University of Oxford for two years.

Upton said the EchoGo system will make Ultromics the first tech company to use AI for automated strain analysis, which is applicable to some 60 million scans per year and will be reimbursable in the U.S. starting in January. He said EchoGo could be a useful tool for physicians of all experience levels looking to learn more about strain calculations and improve their interpretation of echocardiograms.

The company is already looking ahead to next year, when Upton and his team plan to launch the EchoGo Pro—something they’re promising will be “the first AI system able to predict cardiac disease from echocardiography.”

“We are also planning to expand into other geographic regions, including Europe and Asia,” Upton said. “Our goal is to improve patient outcomes through earlier detection of cardiac disease.”

SOURCE

Smartphone app accurately finds, identifies CV implants—and fast

Anicka Slachta | October 07, 2019 | Cardiovascular Imaging

According to the study, the finalized model achieved 95% sensitivity and 98% specificity.

Ferrick et al. said that since their training sample size was somewhat small and limited to a single institution, it would be valuable to validate the model externally. Still, their neural network was able to accurately identify CIEDs on chest radiographs and translate that ability into a phone app.

“Rather than the conventional ‘bench-to-bedside’ approach of translational research, we demonstrated the feasibility of ‘big data-to-bedside’ endeavors,” the team said. “This research has the potential to facilitate device identification in urgent scenarios in medical settings with limited resources.”

SOURCE

https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/smartphone-app-accurately-finds-identifies-cv-implants?utm_source=newsletter&utm_medium=cvb_cardio_imaging

Machine learning cuts cardiac MRI analysis from minutes to seconds

Anicka Slachta | September 24, 2019 | Cardiovascular Imaging

“Cardiovascular MRI offers unparalleled image quality for assessing heart structure and function; however, current manual analysis remains basic and outdated,” Manisty said in a statement. “Automated machine learning techniques offer the potential to change this and radically improve efficiency, and we look forward to further research that could validate its superiority to human analysis.”

It’s estimated that around 150,000 cardiac MRIs are performed in the U.K. each year, she said, and based on that number, her team thinks using AI to read scans could mean saving 54 clinician-days per year at every health center in the country.

“Our dataset of patients with a range of heart diseases who received scans enabled us to demonstrate that the greatest sources of measurement error arise from human factors,” Manisty said. “This indicates that automated techniques are at least as good as humans, with the potential soon to be ‘superhuman’—transforming clinical and research measurement precision.”

SOURCE

https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/machine-learning-speeds-cardiac-mri-analysis?utm_source=newsletter&utm_medium=cvb_cardio_imaging

General SOURCE

From: Cardiovascular Business <news@mail.cardiovascularbusiness.com>

Reply-To: Cardiovascular Business <news@mail.cardiovascularbusiness.com>

Date: Tuesday, December 17, 2019 at 9:31 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Cardiovascular Imaging | December 2019

Read Full Post »

Genetic Testing in CVD and Precision Medicine

Posted in Congenital Heart Disease, Frontiers in Cardiology and Cardiovascular Disorders, Genomic Testing: Methodology for Diagnosis, Origins of Cardiovascular Disease on December 16, 2019| Leave a Comment »

Genetic Testing in CVD and Precision Medicine, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Genetic Testing in CVD and Precision Medicine

Reporter: Aviva Lev-Ari, PhD, RN

 

See


Series A: e-Books on Cardiovascular Diseases 

Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC

VOLUME THREE

Etiologies of Cardiovascular Diseases:

Epigenetics, Genetics and Genomics

http://www.amazon.com/dp/B018PNHJ84

by  

Larry H Bernstein, MD, FCAP, Senior Editor, Author and Curator

and

Aviva Lev-Ari, PhD, RN, Editor and Curator

Genetic Testing in CVD and Precision Medicine

Based on

. 2018 Apr; 3(2): 313–326.
Published online 2018 May 30. doi: 10.1016/j.jacbts.2018.01.003
PMCID: PMC6059349
PMID: 30062216

Cardiovascular Precision Medicine in the Genomics Era

Alexandra M. Dainis, BSa and Euan A. Ashley, BSc, MB ChB, DPhila,b,c,∗
Author information

 

In 2010, we introduced an approach to the evaluation of a personal genome in a clinical context . A patient with a family history of coronary artery disease (CAD) and sudden death was evaluated by a cardiac clinical team in conjunction with whole genome sequencing and interpretation. The genomic analysis revealed an increased genetic risk for myocardial infarction and type 2 diabetes. In addition, a pharmacogenomics analysis was performed to assess how the genetics of the patient might influence response to certain drugs, including lipid-lowering therapies and warfarin . This clinical assessment, which focused heavily on cardiovascular risk, suggested that whole genome sequencing might provide clinically relevant information for patients.

A 2011 joint statement from the Heart Rhythm Society and the European Heart Rhythm association recommended genetic testing as a class I indication for patients with a number of channelopathies and cardiomyopathies, including long QT syndrome (LQTS), arrhythmogenic right ventricular cardiomyopathy, familial dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy (HCM) . Similarly, a statement from the American Heart Association and the American College of Cardiology recommended genetic testing for HCM, DCM, and thoracic aortic aneurysms to facilitate familial cascade screening and deduce causative mutations , .

The diagnostic power of genetic testing is significant across the spectrum of CVDs, ranging from cardiomyopathies to life-threatening arrhythmias , , . In the clinic, genetic testing can:

  • 1.

    clarify disease diagnoses: genetic testing can help to clarify the diagnosis of diseases that cause similar clinical presentation (e.g., cardiac hypertrophy could be TTR amyloidosis, Fabry disease, or sarcomeric HCM);

  • 2.

    facilitate cascade screening: genetic testing can help to identify relatives at risk for CVD before disease symptoms manifest if a disease-associated variant is found in a proband and then screened for in relatives;

  • 3.

    direct more precise therapy: genetic testing can help physicians choose appropriate treatments and plan appropriate timing of those treatments. For example, inherited connective tissue disease due to variants in ACTA2, MYH11, or TGFBR2 might prompt consideration of surgical intervention at a smaller aortic aneurysm diameter ; and

  • 4.

    identify patients for targeted therapies: targeted medical therapies, including antibody-based therapeutics, gene editing, and silencing technologies, are available or under development for several genetic diseases, including LQTS, Duchenne muscular dystrophy (DMD), TTR cardiac amyloidosis , and Fabry disease , .

REFERENCES

7. Ashley E.A., Butte A.J., Wheeler M.T. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–1535. [PMC free article] [PubMed] []
8. Ackerman M.J., Priori S.G., Willems S. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) Europace. 2011;13:1077–1109. [PubMed] []
9. Gersh B.J., Maron B.J., Bonow R.O. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2703–2738. [PubMed] []
10. Harper A.R., Parikh V.N., Goldfeder R.L., Caleshu C., Ashley E.A. Delivering clinical grade sequencing and genetic test interpretation for cardiovascular medicine. Circ Cardiovasc Genet. 2017;10(2) [PubMed] []
11. Walsh R., Thomson K.L., Ware J.S. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19:192–203. [PMC free article] [PubMed] []
12. Sturm A.C., Hershberger R.E. Genetic testing in cardiovascular medicine: current landscape and future horizons. Curr Opin Cardiol. 2013;28:317–325. [PubMed] []
13. Caleshu C., Ashley E. Genetic testing for cardiovascular conditions predisposing to sudden death. In: Wilson M.G., Drezner J., editors. IOC Manual of Sports Cardiology. Wiley & Sons, Ltd; Hoboken, NJ: 2016. pp. 175–186. []
14. Benson M.D., Dasgupta N.R., Rissing S.M., Smith J., Feigenbaum H. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017;24:217–223. [PubMed] []
15. Parikh V.N., Ashley E.A. Next-generation sequencing in cardiovascular disease: present clinical applications and the horizon of precision medicine. Circulation. 2017;135:406–409. [PMC free article] [PubMed] []

SOURCE

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059349/

Read Full Post »

AI Acquisitions by Big Tech Firms Are Happening at a Blistering Pace: 2019 Recent Data by CBIInsights

Posted in An executive's guide to AI, Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Medicine - Applications in Therapeutics, Big Data, Intelligent Information Systems, Transformative Technologies in Healthcare, tagged , , , , , , , , , , , , on December 11, 2019| Leave a Comment »

AI Acquisitions by Big Tech Firms Are Happening at a Blistering Pace: 2019 Recent Data by CBI Insights

Reporter: Stephen J. Williams, Ph.D.

3.4.16

3.4.16   AI Acquisitions by Big Tech Firms Are Happening at a Blistering Pace: 2019 Recent Data by CBI Insights, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 3: AI in Medicine

Recent report from CBI Insights shows the rapid pace at which the biggest tech firms (Google, Apple, Microsoft, Facebook, and Amazon) are acquiring artificial intelligence (AI) startups, potentially confounding the AI talent shortage that exists.

The link to the report and free download is given here at https://www.cbinsights.com/research/top-acquirers-ai-startups-ma-timeline/

Part of the report:

TECH GIANTS LEAD IN AI ACQUISITIONS

The usual suspects are leading the race for AI: tech giants like Facebook, Amazon, Microsoft, Google, & Apple (FAMGA) have all been aggressively acquiring AI startups in the last decade.

Among the FAMGA companies, Apple leads the way, making 20 total AI acquisitions since 2010. It is followed by Google (the frontrunner from 2012 to 2016) with 14 acquisitions and Microsoft with 10.

Apple’s AI acquisition spree, which has helped it overtake Google in recent years, was essential to the development of new iPhone features. For example, FaceID, the technology that allows users to unlock their iPhone X just by looking at it, stems from Apple’s M&A moves in chips and computer vision, including the acquisition of AI company RealFace.

In fact, many of FAMGA’s prominent products and services came out of acquisitions of AI companies — such as Apple’s Siri, or Google’s contributions to healthcare through DeepMind.

That said, tech giants are far from the only companies snatching up AI startups.

Since 2010, there have been 635 AI acquisitions, as companies aim to build out their AI capabilities and capture sought-after talent (as of 8/31/2019).

The pace of these acquisitions has also been increasing. AI acquisitions saw a more than 6x uptick from 2013 to 2018, including last year’s record of 166 AI acquisitions — up 38% year-over-year.

In 2019, there have already been 140+ acquisitions (as of August), putting the year on track to beat the 2018 record at the current run rate.

Part of this increase in the pace of AI acquisitions can be attributed to a growing diversity in acquirers. Where once AI was the exclusive territory of major tech companies, today, smaller AI startups are becoming acquisition targets for traditional insurance, retail, and healthcare incumbents.

For example, in February 2018, Roche Holding acquired New York-based cancer startup Flatiron Health for $1.9B — one of the largest M&A deals in artificial intelligence. This year, Nike acquired AI-powered inventory management startup Celect, Uber acquired computer vision company Mighty AI, and McDonald’s acquired personalization platform Dynamic Yield.

Despite the increased number of acquirers, however, tech giants are still leading the charge. Acquisitive tech giants have emerged as powerful global corporations with a competitive advantage in artificial intelligence, and startups have played a pivotal role in helping these companies scale their AI initiatives.

Apple, Google, Microsoft, Facebook, Intel, and Amazon are the most active acquirers of AI startups, each acquiring 7+ companies.

To read more on recent Acquisitions in the AI space please see the following articles on this Open Access Online Journal

Diversification and Acquisitions, 2001 – 2015: Trail known as “Google Acquisitions” – Understanding Alphabet’s Acquisitions: A Sector-By-Sector Analysis

Clarivate Analytics expanded IP data leadership by new acquisition of the leading provider of intellectual property case law and analytics Darts-ip

2019 Biotechnology Sector and Artificial Intelligence in Healthcare

Forbes Opinion: 13 Industries Soon To Be Revolutionized By Artificial Intelligence

Artificial Intelligence and Cardiovascular Disease

Multiple Barriers Identified Which May Hamper Use of Artificial Intelligence in the Clinical Setting

Top 12 Artificial Intelligence Innovations Disrupting Healthcare by 2020

The launch of SCAI – Interview with Gérard Biau, director of the Sorbonne Center for Artificial Intelligence (SCAI).

Read Full Post »

Older Posts »